

When HAE Attacks...

Count on Plasma-Free

 **RUCONEST**<sup>®</sup>  
C1 esterase inhibitor (recombinant)



#### **INDICATION**

RUCONEST<sup>®</sup> is a C1 esterase inhibitor (recombinant) indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

#### **IMPORTANT SAFETY INFORMATION**

RUCONEST<sup>®</sup> (C1 esterase inhibitor [recombinant]) is not for everyone. Do not take RUCONEST if you have a known history of allergy to rabbits or products from rabbits. Do not take RUCONEST if you have a history of life-threatening immediate allergic reactions to C1 esterase inhibitor preparations, including anaphylaxis.

Please see Important Safety Information on the following pages and accompanying full Prescribing Information, including Patient Product Information [here](#), or visit [www.ruconest.com](http://www.ruconest.com).

 **RUCONEST**<sup>®</sup>  
C1 esterase inhibitor (recombinant)

# About Hereditary Angioedema

## UNDERSTANDING HAE

Whether you have just been diagnosed or have been living with hereditary angioedema (HAE) for some time, it's important to understand the disease and to be prepared for your next attack.

Hereditary angioedema causes repeated episodes of “unexplained” swelling that can occur at any time in almost any part of the body, including the hands, feet, stomach, face, and throat. These attacks are often painful and disrupt normal daily life. Fortunately, there are effective treatments.

Hereditary angioedema is not an allergy but rather an inherited disease that can also occur without a family history. People with HAE often have their first attack early in life, and symptoms often increase around puberty. Hereditary angioedema is caused by not having enough of a blood protein called C1 esterase inhibitor (C1-INH) or by C1-INH that isn't working properly. This prevents the cascade of events in the body that leads to symptoms of an attack.

## TREAT AT THE FIRST SIGN OF AN ATTACK

Because HAE attacks are unpredictable in location, duration, and severity, it is important to treat all attacks as early as possible.

Learn to recognize the early signs that an attack may be coming. These vary from person to person and may include fatigue, rash, stomach upset, muscle and joint pain, cramps, numbness or tingling, and headache.

You may also come to recognize certain events as “triggers” of an attack. These include anxiety, stress, minor injuries, dental procedures, medications, infections, and hormonal changes, such as those occurring during pregnancy or menstruation.

## HAVE A PLAN

**In addition to being aware of warning signs for an impending attack, you should have a treatment plan in place to address each HAE attack as soon as it occurs.**

Work with your healthcare provider to ensure you have a treatment plan in place, or therapy available in the event of an HAE attack.

Many treatments can be self-administered or administered by your caregiver. With an effective plan in place, you'll feel prepared to cope with your next HAE attack.

## Why RUCONEST?



The **ONLY PLASMA-FREE** C1-INH, with no risk of transmission of human viruses



Approx 9 of 10 people needed **ONE DOSE**



**RAPID ONSET OF RELIEF** with a median time of 75 to 90 minutes



Symptom relief was sustained for **AT LEAST 3 DAYS** in 93% of attacks



**RELIABLE SUPPLY** with a large reserve

### INDICATION

RUCONEST® is a C1 esterase inhibitor (recombinant) indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

### HOW TO GET STARTED

After your healthcare provider submits a RUCONEST SOLUTIONS Patient Enrollment form, you can expect:

- 1 A welcome call from your dedicated nurse case manager to review services available
- 2 A free trial of RUCONEST<sup>a</sup> and administration training available by your RUCONEST Patient Advocate
- 3 Coordination of financial support and ongoing shipments from your specialty pharmacy
- 4 Ongoing support throughout your treatment journey

<sup>a</sup>Patients new to RUCONEST may be eligible for a free trial (up to 4 vials or one dose). Free trial offer is subject to modification or cancellation at any time, with or without notice.

### IMPORTANT SAFETY INFORMATION

If you experience hives, pale red, raised, itchy bumps (urticaria), tightness of the chest, wheezing, low blood pressure (hypotension), and/or anaphylaxis during or after injection of RUCONEST, discontinue RUCONEST and immediately contact your doctor. These may be signs and symptoms of allergic reactions.

3 Please see Important Safety Information on the following pages and accompanying full Prescribing Information, including Patient Product Information [here](#), or visit [www.ruconest.com](http://www.ruconest.com).

 **RUCONEST**<sup>®</sup>  
C1 esterase inhibitor (recombinant)

# Learning to Administer RUCONEST

RUCONEST SOLUTIONS offers services to help you get started with RUCONEST and support you throughout your treatment journey




## DEDICATED AND INDIVIDUALIZED SUPPORT

- ▶ As a RUCONEST patient, you are eligible for training on how to administer
- ▶ Training sessions are led by licensed nurses and are held at your convenience in the comfort of your home<sup>a</sup>
- ▶ You and your caregiver can receive as many training sessions as you need to become comfortable with administration
- ▶ On-demand infusion services can be available during an attack

No matter your question, our team of skilled nurses can help you navigate coverage, access, and educational needs.

<sup>a</sup>Availability subject to your geographic location.



## IMPORTANT SAFETY INFORMATION

Products similar to RUCONEST have been associated with thromboembolic events. Before taking RUCONEST, please notify your doctor if you have an indwelling venous catheter/access device, history of blood clot (thrombosis), been told you have thickening of the walls of your arteries (atherosclerosis), use oral contraceptives

(i.e. estrogen or progesterone), are extremely overweight and have significant difficulty moving around.

If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking RUCONEST.

4 Please see Important Safety Information on the following pages and accompanying full Prescribing Information, including Patient Product Information [here](#), or visit [www.ruconest.com](http://www.ruconest.com).

 **RUCONEST**<sup>®</sup>  
C1 esterase inhibitor (recombinant)

## Additional Resources

---



### FOR FURTHER INFORMATION

---

- ▶ Contact your healthcare provider or your RUCONEST nurse case manager
- 



### Call RUCONEST SOLUTIONS

**Phone:**

1-855-613-4HAE (4423)

**Fax:**

1-855-423-5757

**Hours of Operation:**

8 AM-8 PM EST,  
Monday-Friday

---

**RUCONEST  
SOLUTIONS**

Expertise. Delivered personally.

**1-855-613-4423**

---

The RUCONEST SOLUTIONS patient support program is not intended to be a substitute for regular consultation by you or your loved ones with a healthcare prescriber regarding management of your HAE and your RUCONEST treatment.



### Visit RUCONEST.COM

**Visit these patient support sites:**

[haea.org](http://haea.org)

[haei.org](http://haei.org)

[angioedemacenter.com](http://angioedemacenter.com)

---

### IMPORTANT SAFETY INFORMATION

The most common RUCONEST side effects in clinical studies include: headache, nausea, and diarrhea. Serious side effect anaphylaxis has been reported in RUCONEST clinical studies.

5 Please see Important Safety Information on the following pages and accompanying full Prescribing Information, including Patient Product Information [here](#), or visit [www.ruconest.com](http://www.ruconest.com).

 **RUCONEST**<sup>®</sup>  
C1 esterase inhibitor (recombinant)

## INDICATION

RUCONEST® is a C1 esterase inhibitor (recombinant) indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

## IMPORTANT SAFETY INFORMATION

RUCONEST® (C1 esterase inhibitor [recombinant]) is not for everyone. Do not take RUCONEST if you have a known history of allergy to rabbits or products from rabbits. Do not take RUCONEST if you have a history of life-threatening immediate allergic reactions to C1 esterase inhibitor preparations, including anaphylaxis.

If you experience hives, pale red, raised, itchy bumps (urticaria), tightness of the chest, wheezing, low blood pressure (hypotension), and/or anaphylaxis during or after injection of RUCONEST, discontinue RUCONEST and immediately contact your doctor. These may be signs and symptoms of allergic reactions.

Products similar to RUCONEST have been associated with thromboembolic events. Before taking RUCONEST, please notify your doctor if you have an indwelling venous catheter/access device, history of blood clot (thrombosis), been told you have thickening of the walls of your arteries (atherosclerosis), use oral contraceptives (i.e. estrogen or progesterone), are extremely overweight and have significant difficulty moving around.

If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking RUCONEST.

The most common RUCONEST side effects in clinical studies include: headache, nausea, and diarrhea. Serious side effect anaphylaxis has been reported in RUCONEST clinical studies.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact Pharming U.S. toll-free:

**(844) 474-2764** Main corporate number

**(800) 930-5221** Pharmacovigilance, product complaints, medical information

Please see accompanying full Prescribing Information, including Patient Product Information [here](#), or visit [www.ruconest.com](http://www.ruconest.com).



RUCONEST is a registered trademark of Pharming Intellectual Property, B.V.  
© 2017 Pharming Healthcare, Inc. RUC.USA.17.031 Printed in USA.

